GSK buys more of Theravance
May 18, 2012Research and Development, Sales and Marketing COPD, Cellzome, GSK, Relovair, Theravance
GlaxoSmithKline now owns more than a quarter of biopharma company Theravance after shelling out nearly $213 million to buy ten …
OPEN Health invests in Harvey Walsh
May 18, 2012Medical Communications Harvey Walsh, Open Health
Harvey Walsh, a market access and healthcare intelligence company, is to join forces with OPEN Health, the healthcare communications group. OPEN Health …
Teva re-elects Chairman of the Board
May 18, 2012Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Frost, Teva
Teva has announced that its Board of Directors has unanimously voted to re-elect Dr Phillip Frost as Chairman of the …
Plavix loses US patent protection
May 18, 2012Sales and Marketing BMS, FDA, Lipitor, Pfizer, Plavix, Sanofi
Sanofi and Bristol-Myers Squibb’s blood thinner Plavix has lost its patent protection in the US. The drug, which made $6.6 …
NICE to be sidelined on cost effectiveness – once again
May 17, 2012Sales and Marketing NICE, VBP
Health secretary Andrew Lansley has confirmed that NICE will no longer direct the NHS on the cost effectiveness of drugs. …
NICE comes out fighting against appraisal delays story
May 17, 2012Sales and Marketing Daily Mail, Dillon, NHS, NICE, Pfizer, Victrelis
NICE has criticised a report that says the watchdog has taken up to nine years to appraise certain drugs. The …
Medivir appoints commercial executive vice president
May 17, 2012Business Services, Manufacturing and Production, Research and Development, Sales and Marketing Juserius, Medivir
Research-based speciality firm Medivir has appointed Henric Juserius to be the new head of the company’s commercial activities. Juserius who …
Torisel fails in head-to-head study with Nexavar
May 16, 2012Research and Development, Sales and Marketing Bayer, Nexavar, Pfizer, Torisel, inlyta, rcc
Pfizer’s kidney cancer drug Torisel has failed to best Bayer’s Nexavar in a head-to-head trial. The Phase III study was …
Pharma funds drug discovery partnership
May 16, 2012Business Services, Manufacturing and Production, Research and Development, Sales and Marketing Dundee, MRC, drug discovery, funding, partnerships, pharma
Half a dozen pharma firms are contributing £14.4 million to work by Dundee University and the Medical Research Council (MRC) on …
Merck KGaA’s colon cancer drug fails trial
May 16, 2012Research and Development, Sales and Marketing Erbitux, Merck KGaA, Merck Serono, colon cancer
Merck KGaA has suffered a setback with key brand Erbitux as the colerectal cancer drug failed in a late-stage trial. …
Capturing the Brazilian pharma opportunity
May 16, 2012Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Brazil, McKinsey, market access, middle class, pharma
Many multinationals are hungry to sell their goods and services to the emerging markets’ growing middle class, comprising nearly two …
Price cut sways NICE on Zytiga
May 16, 2012Sales and Marketing Jevtana, NICE, Zytiga, prostate cancer
NICE is recommending Janssen’s prostate cancer pill Zytiga, reversing its previous stance. In its final guidance, the watchdog is recommending …
Open Health appoints new digital designer
May 16, 2012Business Services, Medical Communications, Sales and Marketing Open Health
Leo Jacobs has been appointed by Open Health as a digital designer to sit within its OPEN Source team. The …
Merck KGaA sets out savings target as staff threaten to strike
May 15, 2012Research and Development, Sales and Marketing Merck KGaA, R&D, Serono, cuts
Merck KGaA has outlined its plan to make €300 million in savings from its Serono drugs unit, with over half …
CoreLab Partners collaborates at industry conferences worldwide
May 15, 2012Research and Development
Princeton, NJ May 15, 2012 – CoreLab Partners, Inc, a leading independent core lab providing centralized cardiac safety services and …
Genentech taken to task over Avastin production
May 15, 2012Manufacturing and Production Genentech, Phil Taylor, avastin, manufacturing
FDA inspections of a manufacturing facility for Roche/Genentech’s cancer drug Avastin (bevacizumab) uncovered a number of deficiencies which could increase …
ABPI launches new NHS partnership guide
May 15, 2012Medical Communications, Sales and Marketing ABPI, COPD, NHS, code
The Association of the British Pharmaceutical Industry has launched a new guide to explain how pharma and the NHS can …
GlaxoSmithKline to acquire Cellzome for £61 million
May 15, 2012Research and Development, Sales and Marketing Cellzome, Domantis, GSK, R&D
GlaxoSmithKline will expand its platform technology capability with the acquisition of a chemical proteomics company. GSK will acquire those shares …
Synthetic Biologics appoints Carol Reed
May 15, 2012Business Services, Manufacturing and Production, Research and Development, Sales and Marketing Carol Reed, Synthetic
Synthetic Biologics has appointed Carol Reed as senior vice president of Clinical & Regulatory Affairs. In this position Reed will …
Gilenya to stay on US market – but with new safety warnings
May 15, 2012Sales and Marketing EMA, FDA, Novartis, PML, gilenya
The FDA says that Novartis’ multiple sclerosis pill Gilenya should stay on the market, but has added new safety warnings …
Latest content
Five Facts about NHS and primary care
AI in pharma: From lab development to patient impact
